| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Cefozopran hydrochloride, like other β-lactam antibiotics, exerts its antibacterial activity by binding to penicillin-binding proteins (PBPs). This binding inhibits bacterial cell wall synthesis, leading to cell lysis and bacterial death. As a fourth-generation cephalosporin, cefozopran has enhanced activity against both Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. The compound induces cell wall destruction, cell elongation, filamentation, irregular septa formation, and bactericidal, bacteriolytic activity.
|
|---|---|
| ln Vitro |
Cefzopram (SCE-2787) is a fourth-generation cephalosporin that exhibits good efficacy against both Gram-negative and Gram-positive pathogens, including Haemophilus influenzae, as well as methicillin-sensitive Staphylococcus aureus, Enterococcus aureus, and Viridans streptococci. Cefazolin also exhibits good effectiveness against Pseudomonas aeruginosa and other enterococci resistant to cephalosporins [2].
Cefozopran hydrochloride is a potent antibiotic with broad-spectrum antibacterial activity. It is effective against Gram-positive organisms, including methicillin-susceptible staphylococci, enterococci, and viridans group streptococci. It also inhibits most Gram-negative organisms, including Haemophilus influenzae. The compound is particularly effective against Pseudomonas aeruginosa. It is a fourth-generation cephalosporin with broad-spectrum antibacterial activity. |
| ln Vivo |
When administered subcutaneously twice daily for five days to 4-week-old ICR male mice, cefozopran (SCE-2787) (5-80 mg/kg) effectively treats acute respiratory tract disease caused by Klebsiella pneumoniae DT-S Infection. Cefazolin (20–80 mg/kg; subcutaneous injection; twice daily for 7 days; five-week-old CBA/J female mice) was equally efficacious as ceftazidime in a model of chronic respiratory infection caused by Klebsiella pneumoniae 27. 2].
Cefozopran hydrochloride is particularly effective against respiratory, urinary tract, and skin infections and is often utilized in hospital settings for severe infections. As a fourth-generation cephalosporin, it has enhanced activity against both Gram-positive and Gram-negative bacteria. Its broad-spectrum activity makes it suitable for treating severe infections in hospitalized patients. |
| Enzyme Assay |
Cefozopran hydrochloride's activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains. The compound's binding affinity to penicillin-binding proteins (PBPs) can be evaluated using competitive binding assays with radiolabeled penicillin. The compound's bactericidal and bacteriolytic activities can be assessed.
|
| Cell Assay |
Cellular assays for cefozopran hydrochloride are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains, including Gram-positive and Gram-negative organisms. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units. The compound's effects on cell morphology, including elongation, filamentation, and irregular septa formation, can also be studied.
|
| Animal Protocol |
In vivo animal model experiments for cefozopran hydrochloride would involve administration to animal models of infection to evaluate its efficacy. Studies may include models of respiratory, urinary tract, and skin infections. The compound is often utilized in hospital settings for severe infections, suggesting it is effective in treating serious bacterial infections. Such studies are essential for understanding the compound's in vivo behavior and therapeutic potential.
|
| ADME/Pharmacokinetics |
Cefozopran hydrochloride is a fourth-generation cephalosporin antibiotic. Specific pharmacokinetic data is not extensively detailed in the available literature. As a fourth-generation cephalosporin, it is expected to have good tissue penetration, including penetration into the central nervous system. It is administered parenterally.
|
| Toxicity/Toxicokinetics |
Cefozopran hydrochloride is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site. The compound is intended for research use only.
|
| References |
|
| Additional Infomation |
Cefozopran hydrochloride is the hydrochloride form of Cefozopran, a semi-synthetic, broad-spectrum fourth-generation cephalosporin with antibacterial activity. Cefozopran is a fourth-generation cephalosporin antibacterial agent with broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. A 1-methyltetrazolethiol (MTT) group is attached to the C-3 position of the cephalosporin core in Cefozopran.
Cefozopran Hydrochloride (CAS# 113981-44-5) is a semi-synthetic, broad-spectrum, fourth-generation cephalosporin antibiotic. It is effective against a wide range of Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. Cefozopran hydrochloride binds PBPs, induces cell wall destruction, and exhibits bactericidal activity. It is particularly effective against respiratory, urinary tract, and skin infections and is often utilized in hospital settings for severe infections. |
| Molecular Formula |
C19H19CLN9O5S2+
|
|---|---|
| Molecular Weight |
552.9885
|
| Exact Mass |
551.056
|
| CAS # |
113981-44-5
|
| Related CAS # |
Cefozopran;113359-04-9
|
| PubChem CID |
6918222
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
36
|
| Complexity |
960
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CO/N=C(\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-].Cl
|
| InChi Key |
NTJHUKMPVIFDNY-CZNPUCISSA-N
|
| InChi Code |
InChI=1S/C19H17N9O5S2.ClH/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27;/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32);1H/b24-11+;/t12-,17-;/m1./s1
|
| Chemical Name |
(6R,7R)-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrochloride
|
| Synonyms |
SCE2787; SCE-2787; Cefozopran Hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~181.16 mM)
H2O : ≥ 52 mg/mL (~94.20 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8084 mL | 9.0418 mL | 18.0835 mL | |
| 5 mM | 0.3617 mL | 1.8084 mL | 3.6167 mL | |
| 10 mM | 0.1808 mL | 0.9042 mL | 1.8084 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
